S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Sell every Stock except ONE (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
The ONLY Way to Play Markets Like These (Ad)pixel
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
The ONLY Way to Play Markets Like These (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Sell every Stock except ONE (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
The ONLY Way to Play Markets Like These (Ad)pixel
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
The ONLY Way to Play Markets Like These (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Sell every Stock except ONE (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
The ONLY Way to Play Markets Like These (Ad)pixel
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
The ONLY Way to Play Markets Like These (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Sell every Stock except ONE (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
The ONLY Way to Play Markets Like These (Ad)pixel
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
The ONLY Way to Play Markets Like These (Ad)pixel
NASDAQ:ICCC

ImmuCell - ICCC Stock Forecast, Price & News

$8.06
-0.09 (-1.10%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$8.00
$8.10
50-Day Range
$7.70
$9.10
52-Week Range
$7.30
$10.96
Volume
7,798 shs
Average Volume
10,387 shs
Market Capitalization
$62.41 million
P/E Ratio
268.76
Dividend Yield
N/A
Price Target
N/A

ImmuCell MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.08mentions of ImmuCell in the last 14 days
Based on 7 Articles This Week
Insider Trading
Acquiring Shares
$8,000 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.25 out of 5 stars

Medical Sector

1095th out of 1,125 stocks

Diagnostic Substances Industry

17th out of 17 stocks

ICCC stock logo

About ImmuCell (NASDAQ:ICCC) Stock

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Analyst Upgrades and Downgrades

Separately, Aegis reaffirmed a "buy" rating on shares of ImmuCell in a research note on Thursday, June 23rd.

ImmuCell Stock Down 6.9 %

ICCC traded down $0.60 during trading hours on Monday, hitting $8.15. 3 shares of the company's stock were exchanged, compared to its average volume of 10,404. ImmuCell has a 12-month low of $7.30 and a 12-month high of $10.96. The firm has a 50 day moving average of $8.50 and a 200 day moving average of $8.64. The firm has a market cap of $63.11 million, a P/E ratio of 271.76 and a beta of 0.58. The company has a current ratio of 6.91, a quick ratio of 5.07 and a debt-to-equity ratio of 0.30.

ImmuCell (NASDAQ:ICCC - Get Rating) last announced its quarterly earnings data on Thursday, May 12th. The biotechnology company reported $0.09 EPS for the quarter. ImmuCell had a net margin of 1.34% and a return on equity of 0.84%. The company had revenue of $6.00 million for the quarter.

Receive ICCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmuCell and its competitors with MarketBeat's FREE daily newsletter.

ICCC Stock News Headlines

ImmuCell (ICCC) to Release Quarterly Earnings on Thursday
See More Headlines
Receive ICCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmuCell and its competitors with MarketBeat's FREE daily newsletter.

ICCC Company Calendar

Last Earnings
8/12/2021
Today
8/15/2022
Next Earnings (Estimated)
11/21/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ICCC
Employees
60
Year Founded
N/A

Profitability

Net Income
$-80,000.00
Pretax Margin
1.39%

Debt

Sales & Book Value

Annual Sales
$19.24 million
Cash Flow
$0.31 per share
Book Value
$4.21 per share

Miscellaneous

Free Float
7,251,000
Market Cap
$62.41 million
Optionable
Not Optionable
Beta
0.58

Key Executives

  • Mr. Michael F. Brigham (Age 61)
    Pres, CEO, Principal Financial Officer, Treasurer, Sec. & Director
    Comp: $359.59k
  • Ms. Bobbi Jo Brockmann (Age 45)
    VP of Sales & Marketing and Director
    Comp: $299.58k
  • Ms. Elizabeth L. Williams (Age 66)
    VP of Manufacturing Operations
    Comp: $265.12k
  • Elizabeth S. Toothaker
    Director of Fin. & Admin.
  • Mr. A. Gustavo Scaffa
    Sr. Director of Quality
  • John W. Zinckgraf
    Director of Product Devel.













ICCC Stock - Frequently Asked Questions

Should I buy or sell ImmuCell stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ImmuCell in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ICCC shares.
View ICCC analyst ratings
or view top-rated stocks.

How have ICCC shares performed in 2022?

ImmuCell's stock was trading at $8.0001 on January 1st, 2022. Since then, ICCC shares have increased by 0.7% and is now trading at $8.06.
View the best growth stocks for 2022 here
.

When is ImmuCell's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our ICCC earnings forecast
.

How were ImmuCell's earnings last quarter?

ImmuCell Co. (NASDAQ:ICCC) posted its earnings results on Thursday, August, 12th. The biotechnology company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.10. The biotechnology company earned $4.54 million during the quarter. ImmuCell had a net margin of 1.34% and a trailing twelve-month return on equity of 0.84%.

What guidance has ImmuCell issued on next quarter's earnings?

ImmuCell issued an update on its second quarter 2022 earnings guidance on Thursday, July, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $3.90 million-$3.90 million.

What other stocks do shareholders of ImmuCell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmuCell investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Agile Therapeutics (AGRX), Biocept (BIOC), Amarin (AMRN), CorMedix (CRMD), CRISPR Therapeutics (CRSP), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA) and Pfizer (PFE).

What is ImmuCell's stock symbol?

ImmuCell trades on the NASDAQ under the ticker symbol "ICCC."

Who are ImmuCell's major shareholders?

ImmuCell's stock is owned by a number of retail and institutional investors. Top institutional investors include Overbrook Management Corp (0.46%). Insiders that own company stock include David Cunningham and David Scott Tomsche.
View institutional ownership trends
.

How do I buy shares of ImmuCell?

Shares of ICCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ImmuCell's stock price today?

One share of ICCC stock can currently be purchased for approximately $8.06.

How much money does ImmuCell make?

ImmuCell (NASDAQ:ICCC) has a market capitalization of $62.41 million and generates $19.24 million in revenue each year. The biotechnology company earns $-80,000.00 in net income (profit) each year or $0.03 on an earnings per share basis.

How can I contact ImmuCell?

ImmuCell's mailing address is 56 EVERGREEN DR, PORTLAND ME, 04103. The official website for the company is www.immucell.com. The biotechnology company can be reached via phone at (207) 878-2770, via email at iccc@lythampartners.com, or via fax at 207-878-2117.

This page (NASDAQ:ICCC) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.